Research and Markets: MedImmune's Mavrilimumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/lv9gmc/mavrilimumab) has announced the addition of the "Mavrilimumab (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" report to their offering.

Mavrilimumab, also known as CAM3001, is in Phase IIb of development for RA by MedImmune, a subsidiary of AstraZeneca. It is a human mAb targeted against the alpha subunit of the GM-CSF receptor. GM-CSF levels are elevated in the serum, synovial fluid, and synoviocytes of patients with RA. Inhibition of GM-CSF activity is proposed to reduce the activation, differentiation, and recruitment of macrophages and neutrophils in the damaged and inflamed joints of RA patients.

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Mavrilimumab including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Mavrilimumab for the top 6 countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

3.2 Symptoms

3.3 Prognosis

3.4 Quality of Life

4 Disease Management

4.1 Diagnosis and Treatment Overview

4.1.1 Diagnosis

4.1.2 Treatment Guidelines

4.1.3 Leading Prescribed Drugs for the Treatment of RA

4.1.4 Clinical Practice

5 Competitive Assessment

6 Unmet Need and Opportunity

6.1 Overview

6.2 Development of Cost-Effective Therapies

6.3 Biomarkers to Predict Responsiveness to Therapy

6.4 Early Diagnosis of RA

6.5 Personalized Treatment Approach

7 Pipeline Assessment

7.1 Overview

7.2 Promising Drugs in Clinical Development

8 Mavrilimumab

9 Appendix

For more information visit http://www.researchandmarkets.com/research/lv9gmc/mavrilimumab

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders